This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to train the immune system to recognize and attack cancer. The company is developing both personalized and off-the-shelf approaches, aiming to treat a range of tumors. Before taking the helm at Nouscom, Dr Udier built a diverse career across healthcare — working ...
All content for The Pharma Letter Podcast is the property of Simon Wentworth and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to train the immune system to recognize and attack cancer. The company is developing both personalized and off-the-shelf approaches, aiming to treat a range of tumors. Before taking the helm at Nouscom, Dr Udier built a diverse career across healthcare — working ...
AAIC preview with Eisai deputy CCO Michael Irizarry
The Pharma Letter Podcast
22 minutes
2 years ago
AAIC preview with Eisai deputy CCO Michael Irizarry
In the runup to the annual meeting of the Alzheimer’s Association, this week we are speaking with Michael Irizarry, deputy chief clinical officer at Eisai US. At the event in July, there will be plenty to discuss, with recent new data from Eli Lilly (NYSE: LLY) suggesting its anti-amyloid candidate, donanemab, is likely to provide healthy competition for Eisai's (TYO: 4523) own Alzheimer’s product, lecanemab - marketed in the USA as Leqembi. Like Lilly, Eisai has been a pioneer in neurology...
The Pharma Letter Podcast
This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to train the immune system to recognize and attack cancer. The company is developing both personalized and off-the-shelf approaches, aiming to treat a range of tumors. Before taking the helm at Nouscom, Dr Udier built a diverse career across healthcare — working ...
